
Fulcrum Therapeutics FULC
€ 5.83
-3.15%
Geschäftsbericht 2025
hinzugefügt 24.02.2026
Fulcrum Therapeutics Langfristige Verbindlichkeiten 2011-2026 | FULC
Langfristige Verbindlichkeiten Jährlich Fulcrum Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 5.54 M | 233 K | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 5.54 M | 233 K | 2.89 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Veracyte
VCYT
|
810 K | $ 31.01 | -5.46 % | $ 2.44 B | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Vir Biotechnology
VIR
|
28.9 M | $ 8.47 | -5.47 % | $ 1.17 B | ||
|
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Viking Therapeutics
VKTX
|
630 K | $ 32.67 | -4.61 % | $ 3.68 B | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | ||
|
Viridian Therapeutics
VRDN
|
544 K | $ 27.39 | -2.87 % | $ 2.79 B | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
898 M | $ 437.99 | -3.47 % | $ 112 B | ||
|
Avid Bioservices
CDMO
|
21.2 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Verastem
VSTM
|
108 M | $ 5.01 | -5.29 % | $ 347 M | ||
|
VistaGen Therapeutics
VTGN
|
4.16 M | $ 0.56 | -7.23 % | $ 17.3 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
263 M | $ 12.88 | -7.74 % | $ 1.95 B | ||
|
vTv Therapeutics
VTVT
|
44.9 M | $ 38.69 | 2.35 % | $ 152 M | ||
|
Voyager Therapeutics
VYGR
|
179 M | $ 3.97 | -4.0 % | $ 233 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 320.49 | -2.34 % | $ 42 B | ||
|
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
299 K | $ 1.07 | -1.82 % | $ 21.9 M | ||
|
Enochian Biosciences
ENOB
|
425 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Equillium
EQ
|
8.33 M | $ 1.93 | -6.31 % | $ 111 M | ||
|
Amgen
AMGN
|
37.2 B | $ 351.01 | -0.61 % | $ 189 B |